Supplementary Data 1 from Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer

Supplementary Data 1 from Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer

<p>Supplementary Data</p>

Saved in:

書目詳細資料
主要作者:	Alex Chehrazi-Raffle (17079582) (author)
其他作者:	Hanna Tukachinsky (15030806) (author), Eamon Toye (15925708) (author), Smruthy Sivakumar (15053536) (author), Alexa B. Schrock (15047582) (author), Hannah E. Bergom (15925687) (author), Hedyeh Ebrahimi (17079585) (author), Sumanta Pal (17079588) (author), Tanya Dorff (17079591) (author), Neeraj Agarwal (15021102) (author), Brandon A. Mahal (17079594) (author), Geoffrey R. Oxnard (15047597) (author), Justin Hwang (15925675) (author), Emmanuel S. Antonarakis (14971443) (author)
出版:	2025
主題:	Cancer Therapeutic Research and Development Methods and Technology Computational Methods Gene expression profiling Genitourinary Cancers Prostate cancer Liquid Biopsy Translational Research
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

相似書籍

Supplementary Figure 1 from Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer
由: Alex Chehrazi-Raffle (17079582)
出版: (2025)

Figure 1 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
由: Martin Sjöström (14845882)
出版: (2025)

Figure 2 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
由: Martin Sjöström (14845882)
出版: (2025)

Figure 3 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
由: Martin Sjöström (14845882)
出版: (2025)

Figure 4 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
由: Martin Sjöström (14845882)
出版: (2025)

Figure 5 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
由: Martin Sjöström (14845882)
出版: (2025)

Figure 6 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
由: Martin Sjöström (14845882)
出版: (2025)

Figure 7 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
由: Martin Sjöström (14845882)
出版: (2025)

Supplementary Table from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
由: Martin Sjöström (14845882)
出版: (2025)

Supplementary Table from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
由: Martin Sjöström (14845882)
出版: (2025)

Supplementary Table from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
由: Martin Sjöström (14845882)
出版: (2025)

Supplementary Table S1 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
由: Sofie H. Tolmeijer (15313251)
出版: (2025)

Supplementary Table S2 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
由: Sofie H. Tolmeijer (15313251)
出版: (2025)

Supplementary Table S3 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
由: Sofie H. Tolmeijer (15313251)
出版: (2025)

Supplementary Data 1 from Early Changes in Circulating Cell-Free <i>KRAS</i> G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients
由: Cloud P. Paweletz (14960112)
出版: (2025)

Supplementary Data 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
由: Whitney L. Hensing (16461978)
出版: (2025)

Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
由: Francesca Orzan (15055579)
出版: (2025)

Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
由: Francesca Orzan (15055579)
出版: (2025)

Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
由: Francesca Orzan (15055579)
出版: (2025)

Supplementary Figure S1 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
由: Kala Visvanathan (14952973)
出版: (2025)

Supplementary Figure S2 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
由: Kala Visvanathan (14952973)
出版: (2025)

Supplementary Figure S3 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
由: Kala Visvanathan (14952973)
出版: (2025)

Supplementary Figure S4 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
由: Kala Visvanathan (14952973)
出版: (2025)

Supplementary Figure S5 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
由: Kala Visvanathan (14952973)
出版: (2025)

Supplementary Table S1 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
由: Emil Christensen (15054394)
出版: (2025)

Supplementary Table S2 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
由: Emil Christensen (15054394)
出版: (2025)

Supplementary Table S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
由: Stephanie Lheureux (16797697)
出版: (2025)

Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
由: Stephanie Lheureux (16797697)
出版: (2025)

Supplementary Table S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
由: Stephanie Lheureux (16797697)
出版: (2025)

Supplementary Table S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
由: Stephanie Lheureux (16797697)
出版: (2025)

Supplementary Table S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
由: Stephanie Lheureux (16797697)
出版: (2025)

Supplementary Tables S1-S15 from Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
由: Iris van 't Erve (15054503)
出版: (2025)

Supplementary Data S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
由: Andrew A. Davis (15030032)
出版: (2025)

Table S1 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
由: N. Ari Wijetunga (15056183)
出版: (2025)

Table S2 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
由: N. Ari Wijetunga (15056183)
出版: (2025)

Table S3 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
由: N. Ari Wijetunga (15056183)
出版: (2025)

Table S4 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
由: N. Ari Wijetunga (15056183)
出版: (2025)

Supplemental Table 1 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
由: Morten Lapin (15056728)
出版: (2025)

Supplemental Table 2 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
由: Morten Lapin (15056728)
出版: (2025)

Supplemental Table 3 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
由: Morten Lapin (15056728)
出版: (2025)

Cannot write session to /tmp/vufind_sessions/sess_v89g4ltqlafdid1lbtf7g9cid7